Hadassah

Hadassah Researchers Identify Connection Between National Killer Cell and Cirrhosis

Tuesday, Mar 19 2013

Researchers at the Hadassah University Medical Center have discovered that over expression of an immune system Natural Killer (NK) cell called Neuroligin 4 can trigger cirrhosis of the liver by preventing the body from combating scarring. The Hadassah study compared blood samples from dozens of patients with cirrhosis to those of a healthy control group. "In their healthy form, the Neuroligin cells kill the scar-tissue cells," reports Prof. Rifaat Safadi, head of Hadassah's Liver Unit and this study. In the over expression scenario, he explains, "a mechanism is put into operation that keeps the cells from doing their unscarring work."

Several years ago, the same research team found that intact NK cells are good for the liver and prevent cirrhosis. The finding was published in the February 2006 issue of The Journal of Hepatology and also reported by a group of researchers at the National Institutes of Health in the United States. Next, Hadassah's researchers plan to investigate whether mutations of Neuroligin 4 also increase the risk of cirrhosis.

Hadasit, Hadassah's Technology Transfer Company, has already patented Neuroligin 4 in hopes of using it to develop treatments to fend off liver disease.


Read the story in Haaretz here>>

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jul 11 2018

Improving Kidney Health of Premature Babies

Is the TV hit show Grey's Anatomy taking its inspiration from Hadassah Hospital? After all, cast members did visit Hadassah Ein Kerem in 2011. Dr. Oded Volovelsky, Head of Hadassah's new Pediatric Nephrology Unit says, only half-jokingly, that TV doc Meredith Grey might have read his research.

READ MORE ›
alt_text

Wednesday, Jul 11 2018

Hadassah Cancer Specialists Explore Link Between Colorectal Cancer and BRCA Mutations

Looking further into the link between colorectal cancer and BRCA 1 and 2 genetic mutations, researchers from the Hadassah Medical Center’s Sharett Institute of Oncology, together with colleagues from Chaim Sheba Medical Center, analyzed data from 32 patients with lower gastrointestinal cancers.

READ MORE ›
alt_text

Monday, Jul 9 2018

World Hepatitis Day: Hadassah’s Contribution to the Global Battle Against this Disease

“Hadassah Medical Organization's (HMO) greatest contribution to the global battle against Hepatitis are the vaccines that have been developed here,” said Prof. Daniel Shouval, as we mark World Hepatitis Day on July 28.

READ MORE ›
alt_text

Tuesday, Jul 3 2018

Prioritizing Treatment Options in Breast Cancer

When a patient with metastatic breast cancer fails to respond to conventional treatment and gene analysis identifies several targetable molecular mutations, how do you prioritize treatment options?

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More